Clinical Trial of Vaccine, IO102, Plus Keytruda in Advanced NSCLC Patients Planned
News
IO Biotech and Merck & Co recently signed an agreement to assess IO Biotech’s lead candidate IO102, an anti-cancer vaccine, in combination with Keytruda (pembrolizumab) in patients with metastatic non-small cell ... Read more